These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36618081)

  • 1. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
    Toledo-Romaní ME; García-Carmenate M; Valenzuela-Silva C; Baldoquín-Rodríguez W; Martínez-Pérez M; Rodríguez-González M; Paredes-Moreno B; Mendoza-Hernández I; González-Mujica Romero R; Samón-Tabio O; Velazco-Villares P; Bacallao-Castillo JP; Licea-Martín E; Rodríguez-Ortega M; Herrera-Marrero N; Caballero-González E; Egües-Torres L; Duartes-González R; García-Blanco S; Pérez-Cabrera S; Huete-Ferreira S; Idalmis-Cisnero K; Fonte-Galindo O; Meliá-Pérez D; Rojas-Remedios I; Doroud D; Gouya MM; Biglari A; Fernández-Castillo S; Climent-Ruiz Y; Valdes-Balbín Y; García-Rivera D; Van der Stuyft P; Verez-Bencomo V;
    Lancet Reg Health Am; 2023 Feb; 18():100423. PubMed ID: 36618081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
    Toledo-Romani ME; García-Carmenate M; Verdecia-Sánchez L; Pérez-Rodríguez S; Rodriguez-González M; Valenzuela-Silva C; Paredes-Moreno B; Sanchez-Ramirez B; González-Mugica R; Hernández-Garcia T; Orosa-Vázquez I; Díaz-Hernández M; Pérez-Guevara MT; Enriquez-Puertas J; Noa-Romero E; Palenzuela-Diaz A; Baro-Roman G; Mendoza-Hernández I; Muñoz Y; Gómez-Maceo Y; Santos-Vega BL; Fernandez-Castillo S; Climent-Ruiz Y; Rodríguez-Noda L; Santana-Mederos D; García-Vega Y; Chen GW; Doroud D; Biglari A; Boggiano-Ayo T; Valdés-Balbín Y; Rivera DG; García-Rivera D; Vérez-Bencomo V;
    Med; 2022 Nov; 3(11):760-773.e5. PubMed ID: 35998623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
    Toledo-Romaní ME; Valenzuela-Silva C; Montero-Díaz M; Iñiguez-Rojas L; Rodríguez-González M; Martínez-Cabrera M; Puga-Gómez R; German-Almeida A; Fernández-Castillo S; Climent-Ruiz Y; Santana-Mederos D; López-González L; Morales-Suárez I; Doroud D; Valdés-Balbín Y; García-Rivera D; Van der Stuyft P; Vérez-Bencomo V
    Lancet Reg Health Am; 2024 Jun; 34():100750. PubMed ID: 38699214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Eugenia-Toledo-Romaní M; Verdecia-Sánchez L; Rodríguez-González M; Rodríguez-Noda L; Valenzuela-Silva C; Paredes-Moreno B; Sánchez-Ramírez B; Pérez-Nicado R; González-Mugica R; Hernández-García T; Bergado-Baez G; Pi-Estopiñán F; Cruz-Sui O; Fraga-Quintero A; García-Montero M; Palenzuela-Díaz A; Baró-Román G; Mendoza-Hernández I; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; Ramírez Gonzalez U; García-Vega Y; Pérez-Massón B; Guang-Wu-Chen ; Boggiano-Ayo T; Ojito-Magaz E; Rivera DG; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V; ; Gómez-Maceo Y; Reyes-Matienzo R; Manuel Coviella-Artime J; Morffi-Cinta I; Martínez-Pérez M; Castillo-Quintana I; Garcés-Hechavarría A; Valera-Fernández R; Martínez-Bedoya D; Garrido-Arteaga R; Cardoso-SanJorge F; Quintero Moreno L; Ontivero-Pino I; Teresa Pérez-Guevara M; Morales-García M; Noa-Romero E; Orosa-Vázquez I; Díaz-Hernández M; Rojas G; Tundidor Y; García-López E; Muñoz-Morejon Y; Galano-Frutos E; Rodríguez-Alvarez J; Arteaga A; Medina Nápoles M; Espi Ávila J; Fontanies Fernández M
    Vaccine; 2022 Jul; 40(31):4220-4230. PubMed ID: 35691871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
    Hernández-Bernal F; Ricardo-Cobas MC; Martín-Bauta Y; Rodríguez-Martínez E; Urrutia-Pérez K; Urrutia-Pérez K; Quintana-Guerra J; Navarro-Rodríguez Z; Piñera-Martínez M; Rodríguez-Reinoso JL; Chávez-Chong CO; Baladrón-Castrillo I; Melo-Suárez G; Batista-Izquierdo A; Pupo-Micó A; Mora-Betancourt R; Bizet-Almeida J; Martínez-Rodríguez MC; Lobaina-Lambert L; Velázquez-Pérez VM; Soler-Díaz J; Laurencio-Vallina S; Meriño-Hechavarría T; Carmenaty-Campos N; Rodríguez-Montero E; Limonta-Fernández M; Alonso-Valdés M; Hernández-Rodríguez R; Pimentel-Vázquez E; Catasús-Álvarez KM; Cabrera-Núñez MV; Ayala-Ávila M; Muzio-González VL;
    Lancet Reg Health Am; 2023 May; 21():100497. PubMed ID: 37192953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
    Mostafavi E; Eybpoosh S; Karamouzian M; Khalili M; Haji-Maghsoudi S; Salehi-Vaziri M; Khamesipour A; Jalali T; Nakhaeizadeh M; Sharifi H; Mansoori Y; Keramat F; Ghodrati S; Javanian M; Doroud D; Omrani MD; Asadi H; Pouriayevali MH; Ghasemian R; Farshidi H; Pourahmad M; Ghasemzadeh I; Mounesan L; Darvishian M; Mirjalili MR; Toledo-Romani ME; Valenzuela-Silva C; Verez-Bencomo V; Gouya MM; Emadi-Koochak H; Haghdoost AA; Biglari A;
    JAMA Netw Open; 2023 May; 6(5):e2310302. PubMed ID: 37133864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
    Puga-Gómez R; Ricardo-Delgado Y; Rojas-Iriarte C; Céspedes-Henriquez L; Piedra-Bello M; Vega-Mendoza D; Pérez NP; Paredes-Moreno B; Rodríguez-González M; Valenzuela-Silva C; Sánchez-Ramírez B; Rodríguez-Noda L; Pérez-Nicado R; González-Mugica R; Hernández-García T; Fundora-Barrios T; Echevarría MD; Enriquez-Puertas JM; Infante-Hernández Y; Palenzuela-Díaz A; Gato-Orozco E; Chappi-Estévez Y; Francisco-Pérez JC; Suarez-Martinez M; Castillo-Quintana IC; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; García-Vega Y; Toledo-Romani ME; Doroud D; Biglari A; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V;
    Int J Infect Dis; 2023 Jan; 126():164-173. PubMed ID: 36403819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
    Cinza-Estévez Z; Resik-Aguirre S; Figueroa-Baile NL; Oquendo-Martínez R; Campa-Legrá I; Tejeda-Fuentes A; Rivero-Caballero M; González-García G; Chávez-Chong CO; Alonso-Valdés M; Hernández-Bernal F; Lemos-Pérez G; Campal-Espinosa A; Freyre-Corrales G; Benítez-Gordillo D; Gato-Orozco E; Pérez Bartutis GS; Mesa-Pedroso I; Bueno-Alemani N; Infante-Aguilar E; Rodríguez Reinoso JL; Melo-Suarez G; Limonta-Fernández M; Ayala-Ávila M; Muzio-González VL;
    EClinicalMedicine; 2023 Sep; 63():102160. PubMed ID: 37649806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
    Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.